Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-11.44%
0%
-11.44%
6 Months
-15.49%
0%
-15.49%
1 Year
-20.53%
0%
-20.53%
2 Years
-62.2%
0%
-62.2%
3 Years
-71.43%
0%
-71.43%
4 Years
-22.58%
0%
-22.58%
5 Years
-79.24%
0%
-79.24%
C4X Discovery Holdings Plc for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
28.44%
EBIT Growth (5y)
33.30%
EBIT to Interest (avg)
-4.77
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.52
Sales to Capital Employed (avg)
0.41
Tax Ratio
Tax Ratio is Negative%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
16.05%
ROE (avg)
8.59%
Valuation key factors
Factor
Value
P/E Ratio
3
Industry P/E
Price to Book Value
1.23
EV to EBIT
1.85
EV to EBITDA
1.78
EV to Capital Employed
1.48
EV to Sales
0.70
PEG Ratio
0.01
Dividend Yield
NA
ROCE (Latest)
80.23%
ROE (Latest)
42.94%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
Mildly Bullish
Mildly Bearish
OBV
Mildly Bearish
No Trend
Shareholding Snapshot : Dec 2021
Shareholding Compare (%holding) 
Majority shareholders
Non Institution
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 3 Foreign Institutions (19.36%)
Strategic Entities with highest holding
Highest Public shareholder
Annual Results Snapshot (Consolidated) - Jul'23
Jul'23
Jul'22
Change(%)
Net Sales
1.70
2.70
-37.04%
Operating Profit (PBDIT) excl Other Income
-12.90
-10.30
-25.24%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-11.10
-8.20
-35.37%
Operating Profit Margin (Excl OI)
-7,754.40%
-3,898.50%
-385.59%
USD in Million.
Net Sales
YoY Growth in year ended Jul 2023 is -37.04% vs -51.79% in Jul 2022
Consolidated Net Profit
YoY Growth in year ended Jul 2023 is -35.37% vs -115.79% in Jul 2022
About C4X Discovery Holdings Plc 
C4X Discovery Holdings Plc
Pharmaceuticals: Major
C4X Discovery Holdings plc is a drug discovery and development company. The Company is engaged in the provision of technologies to improve the drug discovery process for small molecule therapies. Its discovery portfolio targets addiction, diabetes, inflammatory diseases and oncology, and includes small molecule versions of marketed biologics. Its products include Orexin-1, NRF-2, GPR142, GLP-1, Anti-IL-17, SGC Collaboration and Target 1. Its primary indication for its oral Orexin-1 antagonists is for the treatment of nicotine addiction as an aid to smoking cessation. It has two drug discovery programs targeting inflammatory disorders: oral Nrf-2 activators for the treatment of Chronic Obstructive Pulmonary disease (COPD) and oral/topical IL-17 inhibitors for the treatment of Psoriasis. IL-17 is implicated in multiple inflammatory and autoimmune diseases. Its suite of technologies include Taxonomy3, Conformetrix and MolPlex.
Company Coordinates 
Company Details
Manchester One, 53 Portland Street , MANCHESTER None : M1 3LD
Registrar Details






